Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
Ståhlberg. Co-supervisors at MultiD are Dr. Martin Smelik and Professor Mikael Kubista. The project will be conducted in close collaboration with partners within the academy, industry and health care. Method
-
cutting-edge, high-density data-driven research that impacts academia, industry, and policy worldwide. About the Programme Fellowship: each participant will benefit from a 36-month postdoctoral training
-
contribute to the development of PredictMe’s core product: automated AI-generated health insight reports · Collaborate closely with the academic research group led by Sara Hägg (KI) and the industry partner
-
to work efficiently both independently and as part of a team. Experience from industry or other research infrastructures. We are looking for someone who is Careful, self‑driven, and proactive, with
-
devote oneself to a research project under supervision of experienced researchers and following an individual study plan. A doctoral degree corresponds to four years of full-time study. This is an industry
-
, RISE collaborates with industry, academia, and the public sector to strengthen Sweden’s competitiveness and contribute to a sustainable society. With over 3,300 employees and access to around 100
-
across Swedish academia and industry. Applicants must hold a PhD (or equivalent) prior to the start of employment. For positions at Swedish universities, candidates should normally have obtained their PhD
-
boundaries and promotes collaborations with industry, healthcare, public research organizations and international partners. As a SciLifeLab Fellow, the recruited researcher will be part of the dynamic
-
. English is widely used in academia. Combined with stable public research funding, strong research infrastructure, and close collaboration between academia and industry, this creates a secure and stimulating
-
academic discoveries into drug candidates for further commercial development. The business, which has existed for almost ten years, has, among other things, contributed to >10 new companies and four clinical